6533b838fe1ef96bd12a455c
RESEARCH PRODUCT
Impact of tumor heregulin mRNA expression on outcome of patients with advanced/metastatic squamous NSCLC treated with lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in combination with erlotinib
ÁLvaro TausM. SorensenAndrés CervantesMaria Martinez-garciaSang We KimBirgit BossenmaierIan JamesMartin WeisserJ.h.m. SchellensEnriqueta FelipDidier MeulendijksU. LassenCeline AdessiWolfgang JacobFrancesca MichielinAntonio CallesGeorgina Meneses-lorenteT. FleitasJ.-y. HanMaurizio Ceppisubject
Oncologymedicine.medical_specialtymedicine.drug_classbusiness.industryMrna expressionHematologyLumretuzumabMonoclonal antibodyOncologyInternal medicinemedicineNeuregulinErlotinibbusinessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2016-10-01 | Annals of Oncology |